Amgen Pushes Back At Cancer Patent Suit From J&J Unit
Biopharmaceutical giant Amgen Inc. is denying that one of its patents tied to treatment for bone marrow cancer should be invalidated, after a Johnson & Johnson subsidiary sued to nix the...To view the full article, register now.
Already a subscriber? Click here to view full article